drugset / Trial / NCT04766840
Donor-derived CAR-T Cells in the Treatment of AML Patients
NaSequentialOpen-labelTreatment
Summary
This is a clinical study to evaluate the safety and efficacy of donor-derived CAR-T cells in the treatment of patients with relapsed or refractory acute myeloid leukemia in China.
Timeline
- Start
- 2021-03-01
- Primary completion
- 2023-06-01
- Completion
- 2023-12-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CAR-T cells | Cell therapy | — | Intravenous |
| Background | Cyclophosphamide | Other / unclassified | — | — |
| Background | Fludarabine | Small molecule | — | — |